Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY‐1816, in pancreatic ductal adenocarcinoma

Despite tremendous efforts, the clinical prognosis of pancreatic ductal adenocarcinoma (PDAC) remains disappointing. There is an urgent need to develop more effective treatment strategies to improve the prognosis of patients with PDAC. In this study, we evaluate the anti‐PDAC effects of LY‐1816, a n...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Yang, Wei, Meng, Lingwei, Chen, Kai, Tian, Chenyu, Peng, Bing, Zhong, Lei, Zhang, Chunhui, Yang, Xin, Zou, Jun, Yang, Shengyong, Li, Linli
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6447837/
https://ncbi.nlm.nih.gov/pubmed/30618127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13929
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia